Cortexyme (NASDAQ:CRTX) Shares Pass Above 200-Day Moving Average – Time to Sell?

Cortexyme, Inc. (NASDAQ:CRTX)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.40 and traded as high as $1.50. Cortexyme shares last traded at $1.41, with a volume of 812,249 shares traded.

Cortexyme Stock Up 2.1 %

The stock has a market capitalization of $43.42 million, a price-to-earnings ratio of -0.48 and a beta of 1.40. The company’s 50-day simple moving average is $1.57 and its 200 day simple moving average is $1.41.

About Cortexyme

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.